ipilimumab,nivolumab
bms
['cm-214']
legend presents hrqol data from cm-214 study as prognostic bio marker. it seems pretty logical. could these data indicate pts that derive no specific benefit? #asco22 
??????????? ??? ????????. Passionate and perfectionist. Med Onc with special love to Gyn Onc and prostate cancer.